Generation Bio (NASDAQ:GBIO) Issues Earnings Results

Generation Bio (NASDAQ:GBIO – Get Rating) posted its quarterly earnings data on Thursday. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.03), Fidelity Earnings reports.

Generation Bio Stock Up 0.4 %

Shares of GBIO traded up $0.03 during mid-day trading on Friday, hitting $8.08. The company’s stock had a trading volume of 922,807 shares, compared to its average volume of 358,834. The firm has a 50-day simple moving average of $6.53 and a 200 day simple moving average of $6.27. Generation Bio has a 1-year low of $3.96 and a 1-year high of $28.67.

Hedge Funds Weigh In On Generation Bio

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Swiss National Bank raised its holdings in Generation Bio by 7.4% during the first quarter. Swiss National Bank now owns 87,400 shares of the company’s stock worth $642,000 after purchasing an additional 6,000 shares during the last quarter. Quantbot Technologies LP raised its holdings in Generation Bio by 2,566.7% during the first quarter. Quantbot Technologies LP now owns 8,000 shares of the company’s stock worth $58,000 after purchasing an additional 7,700 shares during the last quarter. Prelude Capital Management LLC purchased a new position in Generation Bio during the first quarter worth $74,000. MetLife Investment Management LLC increased its position in Generation Bio by 476.7% during the first quarter. MetLife Investment Management LLC now owns 19,788 shares of the company’s stock worth $145,000 after buying an additional 16,357 shares in the last quarter. Finally, Jane Street Group LLC increased its position in Generation Bio by 293.1% during the first quarter. Jane Street Group LLC now owns 24,715 shares of the company’s stock worth $181,000 after buying an additional 37,515 shares in the last quarter. 82.00% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Wedbush reaffirmed an “outperform” rating and set a $24.00 price objective on shares of Generation Bio in a research report on Friday. Needham & Company LLC decreased their price objective on Generation Bio from $27.00 to $23.00 and set a “buy” rating for the company in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Generation Bio Company Profile

(Get Rating)

Generation Bio Co, a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.